|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2000-3-23
|
|
pubmed:abstractText |
Tissue eosinophilia prevention represents one of the primary targets to new anti-allergic therapies. As lipoxin A4 (LXA4) and aspirin-triggered 15-epi-LXA4 (ATL) are emerging as endogenous "stop signals" produced in distinct pathologies including some eosinophil-related pulmonary disorders, we evaluated the impact of in situ LXA4/ATL metabolically stable analogues on allergen-induced eosinophilic pleurisy in sensitized rats. LXA4/ATL analogues dramatically blocked allergic pleural eosinophil influx, while concurrently increasing circulating eosinophilia, inhibiting the earlier edema and neutrophilia associated with allergic reaction. The mechanisms underlying this LXA4/ATL-driven allergic eosinophilia blockade was independent of mast cell degranulation and involved LXA4/ATL inhibition of both IL-5 and eotaxin generation, as well as platelet activating factor action. These findings reveal LXA4/ATL as a novel class of endogenous anti-allergic mediators, capable of preventing local eosinophilia.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
164
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2267-71
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:10679058-Allergens,
pubmed-meshheading:10679058-Animals,
pubmed-meshheading:10679058-Anti-Allergic Agents,
pubmed-meshheading:10679058-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:10679058-Aspirin,
pubmed-meshheading:10679058-Cell Migration Inhibition,
pubmed-meshheading:10679058-Cell Movement,
pubmed-meshheading:10679058-Dose-Response Relationship, Immunologic,
pubmed-meshheading:10679058-Eosinophilia,
pubmed-meshheading:10679058-Eosinophils,
pubmed-meshheading:10679058-Female,
pubmed-meshheading:10679058-Hydroxyeicosatetraenoic Acids,
pubmed-meshheading:10679058-Lipoxins,
pubmed-meshheading:10679058-Male,
pubmed-meshheading:10679058-Ovalbumin,
pubmed-meshheading:10679058-Pleurisy,
pubmed-meshheading:10679058-Rats,
pubmed-meshheading:10679058-Rats, Wistar
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking.
|
|
pubmed:affiliation |
Department of Physiology and Pharmacodynamics, Oswaldo Cruz Institute, Fundaçao Oswaldo Cruz, Rio de Janeiro, Brazil.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
